The Food and Drug Administration (FDA) has approved Amvuttra ® (vutrisiran) for the treatment of the cardiomyopathy of ...

The U.S. Food and Drug Administration (FDA) has approved a new drug for a serious heart condition that affects thousands of ...

President Trump selected Susan Monarez, the acting director of the Centers for Disease Control and Prevention, for the ...

CM, expanding its market reach. JP Morgan upgrades the stock, projecting strong sales and a multi-billion opportunity.

JPMorgan upgraded Alnylam (ALNY) to Overweight from Neutral with a price target of $328, up from $280. The firm increased TTR silencer ...

Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price target increased by Canaccord Genuity Group from $385.00 to $390.00 in a report issued on Friday,Benzinga reports. The brokerage ...

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) gapped up prior to trading on Friday after Citigroup raised their price target on the stock from $338.00 to $351.00. The stock ...

Alnylam Pharmaceuticals gains FDA approval for Amvuttra in ATTR-CM, boosting revenue prospects. Click here to read an ...

Along with tafamidis and acoramidis, the drug is now the third for ATTR-CM, but it comes with a whopping price tag of ...

Alnylam stock jumped Friday after the drugmaker won a second Food and Drug Administration approval for its drug, Amvuttra.